Discovery Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Discovery Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,507,668	Closed	-$57.8M	–	100
2016 Q2	$57.8M	Buy	+3,507,668	New	+$56.7M	1.33%	29
2015 Q4	–	Sell	-5,131,840	Closed	-$102M	–	138
2015 Q3	$102M	Buy	5,131,840 +941,500	+22%	+$29.7M	1.13%	27
2015 Q2	$146M	Buy	4,190,340 +3,953,340	+1,668%	+$121M	1.72%	14
2015 Q1	$6.16M	Buy	+237,000	New	+$4.34M	0.07%	84

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Discovery Capital Management's HZNP Position: Q3 2016 in Review

Discovery Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2016, closing a stake of 3,507,668 shares — an estimated $57.8M sold.

Discovery Capital Management first reported a position in HZNP in Q1 2015 and held it in 4 quarters. The position peaked at $146M in Q2 2015. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

Discovery Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2016 after selling out during the quarter.
Discovery Capital Management sold 3,507,668 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $57.8M.
Discovery Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 4 quarters.
Discovery Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $146M in Q2 2015.
232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on Discovery Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.